This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ATNFW 180 Life Sciences (ATNFW) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About 180 Life Sciences Stock (NASDAQ:ATNFW) Get 180 Life Sciences alerts:Sign Up Key Stats Today's Range$0.03▼$0.0550-Day Range$0.03▼$0.0852-Week Range$0.00▼$0.62Volume1.22 million shsAverage Volume501,334 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview 180 Life Sciences (NASDAQ: ATNFW) is a clinical-stage biotechnology company focused on the development of novel treatments for cancer and pain. The company’s scientific approach centers on targeting ion channels and inflammatory pathways to create therapies that address underlying disease mechanisms rather than merely managing symptoms. By leveraging proprietary chemistry and translational research, 180 Life Sciences aims to advance its drug candidates from preclinical studies into human trials. The company’s pipeline includes a lead pain management program designed to modulate the transient receptor potential vanilloid 1 (TRPV1) channel, which plays a key role in the transmission of pain signals. In parallel, 180 Life Sciences is progressing an oncology asset intended to disrupt tumor-supporting microenvironments, with the goal of enhancing the efficacy of existing cancer treatments. Each program has shown promising preclinical data, and the company is preparing to initiate clinical studies in select patient populations. Operating primarily in North America and Europe, 180 Life Sciences maintains research collaborations with academic institutions and contract research organizations to support its discovery and development activities. Headquartered in New York City, the company integrates medicinal chemistry, pharmacology, and translational science to accelerate its drug development timelines. Through strategic partnerships and a focused pipeline, 180 Life Sciences is positioned to bring differentiated therapies to market in areas of high unmet medical need.AI Generated. May Contain Errors. Read More Receive ATNFW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 180 Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATNFW Stock News Headlines180 Life Sciences Stock Slides After-Hours As Ethereum's Decline Triggers Massive Sell-OffAugust 15, 2025 | benzinga.comPeter Thiel-Backed 180 Life Sciences Surged 228% On Ethereum Holdings, ETHZilla Rebrand; Rally Continues After HoursAugust 13, 2025 | benzinga.comI have publicly predicted six major American crashes, before each one happened.Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.October 12 at 1:00 AM | Weiss Ratings (Ad)180 Life Sciences Skyrockets 54% In After-Hours Trading After Raising $156 Million To Buy EthereumAugust 12, 2025 | benzinga.com180 Life Sciences Secures $425 Million to Build ETH TreasuryJuly 31, 2025 | news.bitcoin.com180 Life Sciences Grants Stock Options to ExecutivesJune 20, 2025 | tipranks.com180 Life Sciences Corp. Announces Share Repurchase | ATNF Stock NewsApril 30, 2025 | gurufocus.com180 Life Sciences Appoints New Chief Accounting OfficerFebruary 21, 2025 | tipranks.comSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ATNFW CIK1690080 Web180lifesciences.com Phone650-507-0669FaxN/AEmployees7Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:ATNFW) was last updated on 11/4/2025 by MarketBeat.com Staff. From Our PartnersThe $8,000 Gold Call Every Retirement Saver Needs to Read Right NowGold didn't creep higher—it broke $5,000, a level many analysts thought would hold. Now JPMorgan, the biggest ...Golden Crest Metals | SponsoredFox News: Wall Street Can Seize Your RetirementFox News reported that under current law, legal title to most stocks and bonds sits with a central institution...Monetary Gold | SponsoredUrgent Attention to Executive Order #14363 (Buy This Stock Before Oct. 20thMarc Chaikin, a 60-year Wall Street veteran whose past clients include George Soros and Steve Cohen, built a s...Chaikin Analytics | SponsoredI've seen this movie before (last time: 17,556%)My track record speaks for itself... KDA: 17,556%. PRE: 3,900%. OCEAN: 2,650%. Every single one was called ...Crypto 101 Media | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredUrgent: Invest In ‘Elon’s iPhone’ Before July 22ndEarly Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredFree Ticker: Anthropic's silent partner could soar after record $2 trillion IPOAnthropic's IPO prospectus just leaked, revealing 261 pages tied to a record $2 trillion valuation. Beyond ...Monument Traders Alliance | SponsoredFinally… options made simpleIan Cooper once believed successful options trading meant endless chart-watching, complex strategies, and big ...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 180 Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share 180 Life Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.